Review



antisense oligonucleotides asos  (Innovative Therapies)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Innovative Therapies antisense oligonucleotides asos
    Antisense Oligonucleotides Asos, supplied by Innovative Therapies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antisense+oligonucleotides+asos/antisense+oligonucleotides/pmc13140579-200-3-0
    Average 86 stars, based on 1 article reviews
    antisense oligonucleotides asos - by Bioz Stars, 2026-10
    86/100 stars

    Images

    Related Articles

    Modification:

    Article Title: RNArchitects: how hnRNPs shape neuronal landscapes.
    Article Snippet: .. For example, in ALS, reducing RNA m 6A 34 modification levels has shown potential in inhibiting toxic cytoplasmic protein aggregates in 35 CC EP TE D M AN US CR IP T D ow nloaded from https://academ ic.oup.com /brain/advance-article/doi/10.1093/brain/aw af448/8362251 by guest on 06 D ecem ber 2025 cells expressing mutant FUS 184, whereas the targeted introduction of human DNA Ligase 1 1 to repair mitochondrial DNA damage in FUS mutant cells further illustrates the versatility of 2 these strategies.185 3 Innovative therapies, including antisense oligonucleotides (ASOs), have also emerged as 4 promising interventions for hnRNP-related disorders. ..

    Expressing:

    Article Title: RNArchitects: how hnRNPs shape neuronal landscapes.
    Article Snippet: .. For example, in ALS, reducing RNA m 6A 34 modification levels has shown potential in inhibiting toxic cytoplasmic protein aggregates in 35 CC EP TE D M AN US CR IP T D ow nloaded from https://academ ic.oup.com /brain/advance-article/doi/10.1093/brain/aw af448/8362251 by guest on 06 D ecem ber 2025 cells expressing mutant FUS 184, whereas the targeted introduction of human DNA Ligase 1 1 to repair mitochondrial DNA damage in FUS mutant cells further illustrates the versatility of 2 these strategies.185 3 Innovative therapies, including antisense oligonucleotides (ASOs), have also emerged as 4 promising interventions for hnRNP-related disorders. ..

    Mutagenesis:

    Article Title: RNArchitects: how hnRNPs shape neuronal landscapes.
    Article Snippet: .. For example, in ALS, reducing RNA m 6A 34 modification levels has shown potential in inhibiting toxic cytoplasmic protein aggregates in 35 CC EP TE D M AN US CR IP T D ow nloaded from https://academ ic.oup.com /brain/advance-article/doi/10.1093/brain/aw af448/8362251 by guest on 06 D ecem ber 2025 cells expressing mutant FUS 184, whereas the targeted introduction of human DNA Ligase 1 1 to repair mitochondrial DNA damage in FUS mutant cells further illustrates the versatility of 2 these strategies.185 3 Innovative therapies, including antisense oligonucleotides (ASOs), have also emerged as 4 promising interventions for hnRNP-related disorders. ..



    Similar Products

    antisense oligonucleotides asos  (Innovative Therapies)
    86
    Innovative Therapies antisense oligonucleotides asos
    Antisense Oligonucleotides Asos, supplied by Innovative Therapies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antisense+oligonucleotides+asos/antisense+oligonucleotides/pmc13140579-200-3-0
    Average 86 stars, based on 1 article reviews
    antisense oligonucleotides asos - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    antisense oligonucleotides asos  (Angelman Syndrome Foundation)
    86
    Angelman Syndrome Foundation antisense oligonucleotides asos
    Antisense Oligonucleotides Asos, supplied by Angelman Syndrome Foundation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antisense+oligonucleotides+asos/antisense+asos+oligonucleotides/pmc12936598-204-0-16
    Average 86 stars, based on 1 article reviews
    antisense oligonucleotides asos - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    antisense oligonucleotides asos  (Ionis Pharma)
    86
    Ionis Pharma antisense oligonucleotides asos
    Antisense Oligonucleotides Asos, supplied by Ionis Pharma, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antisense+oligonucleotides+asos/antisense+asos+oligonucleotides/pm41484108-240-8-13
    Average 86 stars, based on 1 article reviews
    antisense oligonucleotides asos - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    antisense oligonucleotide aso tofersen  (Biogen Inc)
    86
    Biogen Inc antisense oligonucleotide aso tofersen
    Antisense Oligonucleotide Aso Tofersen, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antisense+oligonucleotides+asos/for+proxy+tofersen/pm41233143-35-3-8
    Average 86 stars, based on 1 article reviews
    antisense oligonucleotide aso tofersen - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    apo a antisense oligonucleotide aso program  (Novartis)
    86
    Novartis apo a antisense oligonucleotide aso program
    Apo A Antisense Oligonucleotide Aso Program, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antisense+oligonucleotides+asos/a+antisense+apo+aso+oligonucleotide+program/med_rxiv__2025__10__29__25338763-40-3-2
    Average 86 stars, based on 1 article reviews
    apo a antisense oligonucleotide aso program - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    antisense oligonucleotide aso strategies  (Biogen Inc)
    86
    Biogen Inc antisense oligonucleotide aso strategies
    (A) Schematic diagram depicting polyGln encoding genes and their corresponding repeat expansion mutations in the polyGln-SCAs (left) and antibodies designed to test if sense-encoded polySer and <t>antisense-encoded</t> polyLeu RAN proteins are expressed across these polyGln encoding CAG expansion mutations. (B-C) Constructs used to express Flag-polySer and Flag-polyLeu expansion proteins. (D-E) Representative IF images showing co-localization of signal from newly developed α -polySer or α -polyLeu repeat antibodies (green) and α-Flag (red) in transfected HEK293T cells (upper panels). No polySer or polyLeu signal was detected in cells transfected with empty vector (center) or pre-immune serum (lower panels). (F) Our newly developed α-polySer antibody detects nuclear staining (b) in representative images from white matter striatal bundles similar to staining using a previously validated HD-Ser-Ct antibody (d) in HD but not unaffected controls (a,c) or preimmune serum (e) (G) Similarly, IHC using newly developed α-polyLeu and previously validated HD-Leu-Ct antibodies show similar representative staining in HD (g,i) but not control caudate (f,h) or HD tissue stained with pre-immune sera (j). Red, positive staining; purple, counterstain; WMB, white matter bundles.
    Antisense Oligonucleotide Aso Strategies, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antisense+oligonucleotides+asos/antisense+oligonucleotides/bio_rxiv__2025__10__14__682372-125-1-31
    Average 86 stars, based on 1 article reviews
    antisense oligonucleotide aso strategies - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Schematic diagram depicting polyGln encoding genes and their corresponding repeat expansion mutations in the polyGln-SCAs (left) and antibodies designed to test if sense-encoded polySer and antisense-encoded polyLeu RAN proteins are expressed across these polyGln encoding CAG expansion mutations. (B-C) Constructs used to express Flag-polySer and Flag-polyLeu expansion proteins. (D-E) Representative IF images showing co-localization of signal from newly developed α -polySer or α -polyLeu repeat antibodies (green) and α-Flag (red) in transfected HEK293T cells (upper panels). No polySer or polyLeu signal was detected in cells transfected with empty vector (center) or pre-immune serum (lower panels). (F) Our newly developed α-polySer antibody detects nuclear staining (b) in representative images from white matter striatal bundles similar to staining using a previously validated HD-Ser-Ct antibody (d) in HD but not unaffected controls (a,c) or preimmune serum (e) (G) Similarly, IHC using newly developed α-polyLeu and previously validated HD-Leu-Ct antibodies show similar representative staining in HD (g,i) but not control caudate (f,h) or HD tissue stained with pre-immune sera (j). Red, positive staining; purple, counterstain; WMB, white matter bundles.

    Journal: bioRxiv

    Article Title: Repeat associated non-AUG translation as a common mechanism for the polyGln ataxias

    doi: 10.1101/2025.10.14.682372

    Figure Lengend Snippet: (A) Schematic diagram depicting polyGln encoding genes and their corresponding repeat expansion mutations in the polyGln-SCAs (left) and antibodies designed to test if sense-encoded polySer and antisense-encoded polyLeu RAN proteins are expressed across these polyGln encoding CAG expansion mutations. (B-C) Constructs used to express Flag-polySer and Flag-polyLeu expansion proteins. (D-E) Representative IF images showing co-localization of signal from newly developed α -polySer or α -polyLeu repeat antibodies (green) and α-Flag (red) in transfected HEK293T cells (upper panels). No polySer or polyLeu signal was detected in cells transfected with empty vector (center) or pre-immune serum (lower panels). (F) Our newly developed α-polySer antibody detects nuclear staining (b) in representative images from white matter striatal bundles similar to staining using a previously validated HD-Ser-Ct antibody (d) in HD but not unaffected controls (a,c) or preimmune serum (e) (G) Similarly, IHC using newly developed α-polyLeu and previously validated HD-Leu-Ct antibodies show similar representative staining in HD (g,i) but not control caudate (f,h) or HD tissue stained with pre-immune sera (j). Red, positive staining; purple, counterstain; WMB, white matter bundles.

    Article Snippet: While antisense oligonucleotide (ASO) strategies for SMA – and SOD1 – ALS have been tremendously successful, unfortunately, ASO clinical trials for several repeat expansion diseases including HD and C9orf72 ALS/FTD ( https://investors.biogen.com/news-releases/news-release-details/biogen-and-ionis-announce-topline-phase-1-study-results ) have failed.

    Techniques: Construct, Transfection, Plasmid Preparation, Staining, Control